Three innovative drugs by Simcere Pharmaceutical Group (HKG:2096) have been included in China's updated National Reimbursement Drug List, which will become effective Jan. 1, 2025, a Thursday bourse filing said.
Cancer treatment drugs COSELA and ENLITUO have been newly included in the list, while acute ischemic stroke drug Sanbexin is a renewed product, according to the pharmaceutical company.